Genitourinary Cancers

Adjuvant Chemoradiotherapy May Provide Benefit in Locally Advanced Bladder Cancer

Phoebe Starr

July 2016, Vol 7, No 6 - Genitourinary Cancers

In the United States, the standard of care for locally advanced bladder cancer after radical cystectomy is to “consider” adjuvant chemotherapy and ad­juvant radiation. Results of a 3-arm randomized clinical trial showed that adjuvant radiation therapy alone or combined with chemotherapy (ie, chemoradiotherapy) did not significantly improve disease-free survival compared with adjuvant chemotherapy alone. However, the findings hint at benefits for chemoradiotherapy that should be studied further. Brian Baumann, MD, a radiation oncology resident at the University of Pennsylvania, Philadelphia, presented the findings at the 2016 Genitourinary Cancers Symposium. [ Read More ]

Real-World Data Show 2-Year Survival Predicts Long-Term Survival for Metastatic Germ-Cell Testicular Cancer

Phoebe Starr

June 2016, Vol 7, No 5 - Genitourinary Cancers

Contemporary treatment has led to improvements in survival for all patients with metastatic testicular germ-cell tumors (GCTs), including poor-risk patients, although they still have worse survival. A new study shows that if poor-risk patients receive curative therapy and survive for at least 2 years, their survival approaches that of favorable-risk and intermediate-risk patients. The study supports no further routine scanning 2 years after diagnosis in surviving patients. [ Read More ]